Infinimmune announced a research collaboration agreement with Immunome (IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed. Infinimmune rapidly optimizes and engineers early leads into high-fidelity, development-ready therapeutic candidates using its Glimpse and Anthrobody platforms.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
- Immunome initiated with a Buy at Craig-Hallum
- Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
- Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
- Immunome initiated with an Outperform at Evercore ISI